Global Prostate Cancer Therapeutics Market Will Reach USD 17,200 Million By 2024: Zion Market Research

According to the report, global prostate cancer therapeutics market was valued at approximately USD 10,100 million in 2017 and is expected to generate revenue of around USD 17,200 million by end of 2024, growing at a CAGR of around 8% between 2018 and 2024.

| Source: Zion Market Research Zion Market Research

New York, NY, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Prostate Cancer Therapeutics Market by Product Type (Hormonal Therapy [Luteinizing Hormone-releasing Hormone (LHRH) Analogs, Luteinizing Hormone-releasing Hormone (LHRH) Antagonists, and Anti-androgens], Chemotherapy, Targeted Therapy, and Immunotherapy) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024”. According to the report, global prostate cancer therapeutics market was valued at approximately USD 10,100 million in 2017 and is expected to generate revenue of around USD 17,200 million by end of 2024, growing at a CAGR of around 8% between 2018 and 2024.

The uncontrolled growth of prostate gland cells leads to prostate cancer. In the U.S., prostate cancer is the one of most common cancer after skin cancer in men. According to the American Community Survey, in the U.S., prostate cancer was the second foremost cause of death amongst the cancer deaths in men in the U.S. 

Browse through 49 Tables & 18 Figures spread over 130 Pages and in-depth TOC on “Global Prostate Cancer Therapeutics Market Size 2017: Type, Industry Share, Growth, Analysis and Forecast, to 2024”.

Request Free Sample Report of Global Prostate Cancer Therapeutics Market Report @ https://www.zionmarketresearch.com/sample/prostate-cancer-therapeutics-market

The initiatives taken by the top players in partnership with various governments to generate awareness about early clinical symptoms of prostate cancer and accessibility of diagnostic & screening tests such as Digital Rectal Exam (DRE) and Prostate-Specific Antigen (PSA) helps in early disease detection, which is expected to propel the growth of prostate cancer therapeutics market in the near future.  

The global prostate cancer therapeutics market is segmented into product type, distribution channel, and geography. Based on the product type, the prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, targeted therapy, and immunotherapy. The hormone therapy is further segmented as luteinizing hormone-releasing hormone (LHRH) antagonists, anti-androgens, and luteinizing hormone-releasing hormone (LHRH) analogs, which includes Zoladex, Lupron, Eligard, Decapeptyl, and others. Based on chemotherapy, the prostate cancer market is segregated into Jevtana, Mitoxantrone, Taxotere, Estramustine, and others agents. Based on product type, the hormone therapy accounted for the highest share in the global prostate cancer market in 2017 and is expected to remain dominant over the forecast period. Hormonal therapy is also known as androgen deprivation therapy (ADT). The hormone therapy helps to decrease the level of androgens that are male hormones which stimulate the growth of cancer. Suppressing the hormone level, the drugs help to reduce the growth of cancer of prostate. The immunotherapy drugs for prostate cancer are expected to register the highest CAGR in the global market. The rapid adoption and development of immunotherapy drugs is the key factor contributing towards the high growth of segment in the global market. PROSTVAC and INO-5150 SynCon are the new upcoming drugs to market which are currently in pipeline. The introduction of novel drugs is expected to propel the growth of the segment in the global prostate cancer therapeutics market.    

Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/prostate-cancer-therapeutics-market

On the basis of the distribution channel, the prostate cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy distribution channel accounted for the largest share in the global prostate cancer therapeutics market in 2017. The rising number of the patient pool for medical care in hospitals is the chief factor contributing towards the high share of segment in the global market. The online pharmacy is expected to register high CAGR in the global prostate cancer therapeutics market over the forecast period.  

By geography, North America accounted for the highest share in the prostate cancer therapeutics market globally in 2017. The high investment in research & development activities for the development of newer drugs such as targeted therapy and immunotherapy for the treatment of prostate cancer is expected to drive the growth of the market in North America over the forecast period. Moreover, the high prevalence of prostate cancer among the American men contributes towards the growth of prostate cancer therapeutics market globally. According to the American Cancer Society, in American men, the prostate cancer is the second foremost cause of death, after lung cancer. According to their estimations, in 2018, 1 man in 41 is expected die due to prostate cancer. The prostate cancer occurs mainly in American-African and in older men. Among the 10 diagnosed cases, 6 are men aged 65 or older. Moreover, high spending on healthcare and ease of use of better healthcare infrastructure is also expected to contribute towards the large share of North America in the global prostate cancer therapeutics market.

Request Discount on This Report: https://www.zionmarketresearch.com/requestdiscount/prostate-cancer-therapeutics-market

Europe accounted for the second largest share in the global prostate cancer market in 2017. According to the Cancer Research, in 2017, about 11,287 deaths were reported due to prostate cancer in the U.K. In the developed regions, prostate cancer is the most common cause of death due to cancer. The presence of key players operating in the prostate cancer market, strong research base, and high prevalence of prostate cancer in Europe are contributing to the growth of the market in the region. 

Asia Pacific is expected to register the highest CAGR in the global prostate cancer therapeutics market in the coming years. Increasing awareness of prostate cancer is the primary factor expected to drive the growth market in the region. The governments of various countries of Asia Pacific are playing an essential role in generating awareness through online portals and programs which provides comprehensive information about diagnosis and screening & through DRE and PSA blood tests for male patients above 50 years of age. Moreover, improving healthcare infrastructure, adoption of newer technologies, rising investment of key players for the development of new drug therapies for the treatment of prostate cancer is expected to propel the growth of the market over the forecast period.

Browse the full "Prostate Cancer Therapeutics Market by Product Type (Hormonal Therapy [Luteinizing Hormone-releasing Hormone (LHRH) Analogs, Luteinizing Hormone-releasing Hormone (LHRH) Antagonists, and Anti-androgens], Chemotherapy, Targeted Therapy, and Immunotherapy) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024" report at https://www.zionmarketresearch.com/report/prostate-cancer-therapeutics-market

The Middle East and Africa and Latin America, hold the least share in the global prostate cancer therapeutics market but is expected to register a significant growth rate over the forecast period. The less awareness about the diseases and treatment and less affordability are the factors affecting the growth of the market in these regions.

Some of the key players cover in prostate cancer therapeutics market are Amgen, Inc., Pfizer, Inc., Johnson & Johnson, AbbVie, Inc., AstraZeneca, Bayer AG, Sanofi, Ipsen Group, Dendreon Corporation, and Endo Pharmaceuticals, Inc.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/prostate-cancer-therapeutics-market

This report segments the global Prostate cancer therapeutics market as follows:

Global Prostate Cancer Therapeutics Market: Product Type Segment Analysis

  • Hormonal Therapy
    • Luteinizing Hormone-releasing Hormone (LHRH) Analogs
      • Zoladex 
      • Lupron 
      • Eligard 
      • Decapeptyl 
      • Others 
    • Luteinizing Hormone-releasing Hormone (LHRH) Antagonists
    • Anti-androgens
  • Chemotherapy 
    • Jevtana
    • Mitoxantrone
    • Taxotere
    • Estramustine
    • Others 
  • Targeted Therapy 
  • Immunotherapy

Global Prostate Cancer Therapeutics Market: End-User Segment Analysis

  • Hospital Pharmacy Pharmacy
  • Retail Pharmacy
  • Online Pharmacy 

Global Prostate Cancer Therapeutics Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research

Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

Contact Us:

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com

Tags

Prostate Cancer Market Prostate Cancer Industry Prostate Cancer Size Prostate Cancer Share Prostate Cancer 2017

Related Links